查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370907

循環腫瘤細胞市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按技術、按應用、產品、樣本、地區、競爭細分

Circulating Tumor Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology, By Application, By Product, By Specimen, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球循環腫瘤細胞市場在2022年達到98.1億美元的估值，預計在預測期內將大幅成長，到2028年年複合成長率（CAGR）為9.20%，預計2028年將達到165.4億美元。循環腫瘤細胞（CTC）市場圍繞著識別和分析從原發腫瘤分離並進入血液的癌細胞。 CTC 具有重要的診斷和預後價值，可深入了解疾病進展、治療效果以及向身體其他部位的潛在擴散。該市場包含一系列創新技術和方法，旨在從血液樣本中分離、量化和表徵這些稀有細胞。透過實現癌症和治療反應的非侵入性監測，CTC 市場在個人化醫療和治療決策中發揮著至關重要的作用。隨著該領域的進步，微流控、成像技術和分子分析技術的突破有助於提高 CTC 檢測的敏感度和特異性。

主要市場促進因素

轉向個人化醫療

市場概況
預測期 2024-2028
2022 年市場規模 98.1億美元
2028 年市場規模 165.4億美元
2023-2028 年年複合成長率 9.20%
成長最快的細分市場 研究
最大的市場 北美洲

個人化醫療的趨勢強烈推動了對循環腫瘤細胞（CTC）市場的需求。個人化醫療根據患者獨特的遺傳和分子特徵為個別患者量身定做治療方案。 CTC 測試與這種方法無縫結合，為臨床醫生和患者提供了備受追捧的工具。與遵循標準化方法的傳統癌症治療不同，CTC 測試可以即時了解疾病狀態和治療反應。當癌細胞進入血液時，CTC 提供腫瘤遺傳和分子特徵的動態表示。這使得腫瘤學家能夠監測治療效果、檢測抗藥性並對治療計劃做出明智的調整。

CTC 檢測的非侵入性

循環腫瘤細胞 (CTC) 檢測的非侵入性是 CTC 市場需求不斷成長的主要動力。與傳統的侵入性腫瘤活體組織切片不同，CTC 檢測提供了一種微創方式來收集有關患者癌症狀態的關鍵資訊。這對癌症診斷和治療監測具有變革性影響，吸引了醫療保健專業人員和患者的興趣。傳統的活體組織切片可能會導致不適、併發症和恢復時間縮短。相較之下，CTC 檢測只需進行簡單的抽血，即可減少患者的焦慮並消除與侵入性操作相關的風險。

CTC 檢測也解決了定期癌症監測的需求。頻繁監測對於評估治療反應和疾病進展至關重要，但由於侵入性，重複活體組織切片是不切實際的。 CTC 測試可以透過血液樣本進行定期監測，無需侵入性操作即可提供即時見解。這與以患者為中心的護理一致，滿足對破壞性最小的診斷的偏好。

CTC 檢測的非侵入性方法在難以取得組織樣本的挑戰性情況下非常有價值。此外，CTC 測試透過提供對腫瘤異質性的更廣泛了解來補充傳統活體組織切片。這方面有助於擴大癌症篩檢和早期檢測工作，與在最早、最可治療的階段識別癌症的目標保持一致。

癌症盛行率上升

癌症盛行率的增加是循環腫瘤細胞（CTC）市場需求的關鍵驅動力。由於癌症仍然是全球健康挑戰，因此對準確診斷工具的需求至關重要。 CTC 測試透過提供對疾病進展和治療反應的見解來滿足這一需求。世界衛生組織預計，由於人口老化、生活方式的改變和環境因素，癌症發生率將顯著上升。癌症盛行率的不斷上升推動了對早期檢測、治療監測和個人化治療的有效方法的需求。

CTC 檢測透過在腫瘤在成像掃描中可見之前或在症狀出現之前識別血液中的癌細胞來實現早期檢測。早期發現可以早期介入、改善結果並降低發病率。 CTC 測試還透過提供對腫瘤遺傳學和分子特徵的見解來支持治療監測和個人化方法。此外，CTC 測試加速了臨床試驗和藥物開發，並加快了藥物療效和安全性的評估。

癌症盛行率的上升凸顯了個人化治療的重要性。 CTC 測試在這方面發揮關鍵作用，為客製化療法提供對遺傳和分子特徵的見解。隨著癌症發生率的增加，對 CTC 檢測的需求持續成長，使其成為應對癌症挑戰的重要工具。

主要市場挑戰

檢測靈敏度和特異性

檢測靈敏度和特異性對循環腫瘤細胞 (CTC) 市場提出了重大挑戰，影響了 CTC 檢測的準確性和可靠性。 CTC 是血液中少量存在的稀有細胞，因此檢測技術要求很高。平衡靈敏度（檢測低水平的 CTC）和特異性（準確地區分 CTC 與其他細胞）對於有效的 CTC 檢測至關重要。檢測不充分可能會導致假陰性，從而延遲診斷和治療決策。要實現高靈敏度需要更靈敏的技術來檢測數十億正常細胞中的單一 CTC。確保特異性對於避免誤報同樣重要，誤報可能導致不必要的介入和患者焦慮。

實現敏感性和特異性需要持續創新、跨學科合作和嚴格的驗證研究。整合先進的成像、微流體和分子分析可提高 CTC 檢測精度。標準化方案和品質控制確保實驗室之間的一致性。

CTC 的異質性

循環腫瘤細胞 (CTC) 的異質性為 CTC 市場帶來了重大挑戰。 CTC 表現出多種遺傳和表現型特徵，這些特徵在腫瘤內部和腫瘤之間各不相同。應對這項挑戰需要捕獲 CTC 亞群的技術。整合先進的分子分析有助於了解 CTC 多樣性。縱向分析可以追蹤隨時間的變化。

克服 CTC 異質性需要跨學科合作和技術進步。微流控、成像和高通量定序可捕捉不同的 CTC。標準化協議確保一致性。

成本考慮

成本考量會影響 CTC 測試的採用和可近性。先進技術、專業培訓和設備維護都會增加成本。患者對負擔能力和保險範圍的擔憂會影響決策。解決成本挑戰涉及技術開發、合作和規模經濟。創新和合作可以帶來具有成本效益的解決方案。

主要市場趨勢

下一代定序 (NGS) 的整合

次世代定序 (NGS) 整合改變了循環腫瘤細胞 (CTC) 市場。 NGS 分析 CTC 遺傳學，揭示突變、變異和基因表現。這一趨勢增強了對腫瘤的了解，指導治療決策並推進個人化護理。 NGS 捕獲遺傳異質性，識別標靶治療的突變。這一趨勢加速了研究轉化。

用於早期檢測的液體活體組織切片

液體活體組織切片，包括 CTC 檢測，是早期癌症檢測的趨勢。 CTC 檢測可在腫瘤可見或出現症狀之前檢測血液中的癌細胞。這種非侵入性方法可以及時進行干涉，特別是對於侵襲性癌症。液體活體組織切片與標靶治療一致，有助於治療決策。

細分市場洞察

技術： Ctc 檢測和富集技術占主導地位。 「CTC 分析」和「CTC 直接檢測」由於成像和分子分析的進步而受到關注。

應用：臨床/液體活體組織切片領先，徹底改變癌症護理。早期檢測和治療監測推動了採用。

區域洞察

北美由於醫療基礎設施、研究和有利的法規而佔據主導地位。領先機構和產業合作鞏固了其領導地位。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球循環腫瘤細胞市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術分類（CTC 檢測與富集、CTC 直接檢測、CTC 分析）
    • 按應用（臨床/液體活體組織切片、研究）
    • 依產品（設備或系統、試劑盒及試劑、採血管）
    • 依樣本（骨髓、血液、其他體液）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美循環腫瘤細胞市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按產品分類
    • 按樣本
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲循環腫瘤細胞市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按產品分類
    • 按樣本
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區循環腫瘤細胞市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按產品分類
    • 按樣本
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲循環腫瘤細胞市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按產品分類
    • 按樣本
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲循環腫瘤細胞市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按產品分類
    • 按樣本
    • 按國家/地區
  • MEA：國家分析
    • 南非循環腫瘤細胞
    • 沙烏地阿拉伯循環腫瘤細胞
    • 阿拉伯聯合大公國循環腫瘤細胞

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Greiner Bio One International GmbH
    • LineaRx, Inc. (Vitatex, Inc.)
    • Bio-Techne Corporation
    • Biolidics Limited
    • Fluxion Biosciences, Inc.
    • Creatv MicroTech, Inc.
    • Canopus Bioscience Ltd.
    • AVIVA Biosciences Corp
    • Miltenyi Biotec Inc
    • QIAGEN NV

第 16 章：策略建議

簡介目錄
Product Code: 15903

Global Circulating Tumor Cells Market achieved a valuation of USD 9.81 Billion in 2022 and is expected to experience substantial growth during the forecast period, with a Compound Annual Growth Rate (CAGR) of 9.20% until 2028 and expected to reach USD 16.54 Billion in 2028. The Circulating Tumor Cells (CTC) Market revolves around identifying and analyzing cancer cells that detach from primary tumors and enter the bloodstream. CTCs hold significant diagnostic and prognostic value, offering insights into disease progression, treatment effectiveness, and potential spread to other parts of the body. This market encompasses a range of innovative technologies and methods designed to isolate, quantify, and characterize these rare cells from blood samples. By enabling non-invasive monitoring of cancer and treatment response, the CTC market plays a crucial role in personalized medicine and treatment decision-making. As the field advances, breakthroughs in microfluidics, imaging technologies, and molecular analysis techniques contribute to enhancing the sensitivity and specificity of CTC detection.

Key Market Drivers

Shift towards Personalized Medicine

Market Overview
Forecast Period2024-2028
Market Size 2022USD 9.81 Billion
Market Size 2028USD 16.54 Billion
CAGR 2023-20289.20%
Fastest Growing SegmentResearch
Largest MarketNorth America

The trend towards personalized medicine strongly drives the demand for the Circulating Tumor Cells (CTC) Market. Personalized medicine tailors medical treatments to individual patients based on their unique genetic and molecular characteristics. CTC testing aligns seamlessly with this approach, offering a highly sought-after tool for clinicians and patients. Unlike traditional cancer treatments that follow a standardized approach, CTC testing provides real-time insights into disease status and treatment response. As cancer cells enter the bloodstream, CTCs offer a dynamic representation of the tumor's genetic and molecular profile. This empowers oncologists to monitor treatment effectiveness, detect drug resistance, and make informed adjustments to the treatment plan.

Personalized medicine aims to enhance treatment outcomes while minimizing adverse effects. CTC testing guides clinicians in identifying targeted therapies that are more likely to be effective. Analyzing the genetic mutations and markers of CTCs allows healthcare providers to recommend treatments matched to the patient's tumor profile, improving response rates and reducing side effects. Additionally, CTC testing aids in predicting a patient's prognosis by studying changes in CTC genetics over time, providing insights into tumor behavior and aiding treatment decisions.

The demand for CTC testing aligns with advancements in technology, including microfluidic platforms, imaging, and molecular analysis. These innovations enhance the precision of CTC detection, supporting personalized cancer care. As personalized medicine gains momentum, CTC testing becomes increasingly valuable, providing insights into tumor behavior, treatment response, and prognosis.

Non-Invasive Nature of CTC Testing

The non-invasive nature of Circulating Tumor Cells (CTC) testing is a major driver behind the growing demand for the CTC Market. Unlike traditional tumor biopsies that are invasive, CTC testing offers a minimally invasive way to gather critical information about a patient's cancer status. This has transformative implications for cancer diagnosis and treatment monitoring, attracting interest from healthcare professionals and patients. Traditional biopsies can cause discomfort, complications, and recovery time. In contrast, CTC testing involves a simple blood draw, reducing patient anxiety and eliminating risks associated with invasive procedures.

CTC testing also addresses a need for regular cancer monitoring. Frequent monitoring is essential for assessing treatment response and disease progression, but repeated biopsies are impractical due to invasiveness. CTC testing allows regular monitoring through blood samples, offering real-time insights without invasive procedures. This aligns with patient-centric care, meeting the preference for minimally disruptive diagnostics.

The non-invasive approach of CTC testing is valuable in challenging cases where tissue samples are hard to obtain. Additionally, CTC testing complements traditional biopsies by providing a broader understanding of tumor heterogeneity. This aspect contributes to expanding cancer screening and early detection efforts, aligning with the goal of identifying cancer at its earliest, most treatable stage.

Rising Prevalence of Cancer

The increasing prevalence of cancer is a key driver of demand in the Circulating Tumor Cells (CTC) Market. As cancer remains a global health challenge, the need for accurate diagnostic tools is critical. CTC testing addresses this need by offering insights into disease progression and treatment response. The World Health Organization projects a significant rise in cancer incidence due to aging populations, lifestyle changes, and environmental factors. This growing cancer prevalence drives demand for effective methods of early detection, treatment monitoring, and personalized therapies.

CTC testing addresses early detection by identifying cancer cells in the bloodstream before tumors become visible on imaging scans or before symptoms appear. Early detection leads to earlier interventions, improved outcomes, and reduced morbidity. CTC testing also supports treatment monitoring and personalized approaches by offering insights into tumor genetics and molecular characteristics. Additionally, CTC testing accelerates clinical trials and drug development, expediting the assessment of drug efficacy and safety.

The rising cancer prevalence underscores the importance of personalized treatment. CTC testing plays a pivotal role in this context, offering insights into genetic and molecular characteristics for tailored therapies. As cancer rates increase, the demand for CTC testing continues to grow, positioning it as a vital tool in addressing the challenge of cancer.

Key Market Challenges

Detection Sensitivity and Specificity

Detection sensitivity and specificity present significant challenges in the Circulating Tumor Cells (CTC) Market, affecting the accuracy and reliability of CTC testing. CTCs are rare cells present in small quantities in the bloodstream, making their detection technically demanding. Balancing sensitivity (detecting low levels of CTCs) and specificity (accurately distinguishing CTCs from other cells) is crucial for effective CTC testing. Insufficient detection can lead to false negatives, delaying diagnosis and treatment decisions. Achieving high sensitivity requires more sensitive technologies to detect even a single CTC among billions of normal cells. Ensuring specificity is equally important to avoid false positives, which can lead to unnecessary interventions and patient anxiety.

Achieving both sensitivity and specificity requires continuous innovation, interdisciplinary collaboration, and rigorous validation studies. Integrating advanced imaging, microfluidics, and molecular analysis enhances CTC detection precision. Standardized protocols and quality control ensure consistency across laboratories.

Heterogeneity of CTCs

The heterogeneity of Circulating Tumor Cells (CTCs) poses a significant challenge in the CTC Market. CTCs exhibit diverse genetic and phenotypic characteristics that vary within and among tumors. Addressing this challenge requires technologies capturing CTC subpopulations. Integrating advanced molecular analysis helps understand CTC diversity. Longitudinal analysis enables tracking changes over time.

Overcoming CTC heterogeneity requires interdisciplinary collaboration and technology advancements. Microfluidics, imaging, and high-throughput sequencing capture diverse CTCs. Standardized protocols ensure consistency.

Cost Considerations

Cost considerations impact the adoption and accessibility of CTC testing. Advanced technologies, specialized training, and equipment maintenance contribute to costs. Patient concerns about affordability and insurance coverage impact decisions. Addressing cost challenges involves technology development, collaborations, and economies of scale. Innovations and collaborations can lead to cost-effective solutions.

Key Market Trends

Integration of Next-Generation Sequencing (NGS)

Next-Generation Sequencing (NGS) integration transforms the Circulating Tumor Cells (CTC) Market. NGS analyzes CTC genetics, uncovering mutations, variations, and gene expression. This trend enhances tumor understanding, guiding treatment decisions and advancing personalized care. NGS captures genetic heterogeneity, identifying mutations for targeted therapies. This trend accelerates research translation.

Liquid Biopsies for Early Detection

Liquid biopsies, including CTC testing, trend towards early cancer detection. CTC testing detects cancer cells in blood before tumors are visible or symptomatic. This non -invasive approach enables timely interventions, especially for aggressive cancers. Liquid biopsies align with targeted therapies, aiding treatment decisions.

Segmental Insights

Technology: Ctc Detection & Enrichment technology dominates. "CTC Analysis" and "CTC Direct Detection" gain traction due to imaging and molecular analysis advancements.

Application: Clinical/Liquid Biopsy leads, revolutionizing cancer care. Early detection and treatment monitoring drive adoption.

Regional Insights

North America dominates due to healthcare infrastructure, research, and favorable regulations. Leading institutions and industry collaborations solidify its leadership.

Key Market Players

  • Greiner Bio One International GmbH
  • LineaRx, Inc. (Vitatex, Inc.)
  • Bio-Techne Corporation
  • Biolidics Limited
  • Fluxion Biosciences, Inc.
  • Creatv MicroTech, Inc.
  • Canopus Bioscience Ltd.
  • AVIVA Biosciences Corp
  • Miltenyi Biotec Inc
  • QIAGEN NV

Report Scope:

In this report, the Global Circulating Tumor Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Circulating Tumor Cells Market, By Technology:

  • CTC Detection & Enrichment
  • CTC Direct Detection
  • CTC analysis

Circulating Tumor Cells Market, By Application:

  • Clinical/liquid biopsy
  • Research

Circulating Tumor Cells Market, By Product:

  • Devices or Systems
  • Kits & Reagents
  • Blood Collection Tubes

Circulating Tumor Cells Market, By Specimen:

  • Bone Marrow
  • Blood,
  • Other Body Fluids

Circulating Tumor Cells Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Circulating Tumor Cells Market.

Available Customizations:

  • Global Circulating Tumor Cells Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Circulating Tumor Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (CTC Detection & Enrichment, CTC Direct Detection, CTC analysis)
      • 5.2.1.1. By CTC Detection & Enrichment (Immunocapture/label-based, Size-based separation/label-free, Density-based separation, Combined methods)
      • 5.2.1.2. By CTC Direct Detection (Microscopy, SERS, Others)
    • 5.2.2. By Application (Clinical/liquid biopsy, Research)
      • 5.2.2.1. By Clinical/liquid biopsy (Risk assessment, Screening and Monitoring)
      • 5.2.2.2. By Research (Cancer stem cell & tumorigenesis research, Drug/therapy development)
    • 5.2.3. By Product (Devices or Systems, Kits & Reagents, Blood Collection Tubes)
    • 5.2.4. By Specimen (Bone Marrow, Blood, Other Body Fluids)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Circulating Tumor Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Product
    • 6.2.4. By Specimen
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Circulating Tumor Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Product
        • 6.3.1.2.4. By Specimen
    • 6.3.2. Mexico Circulating Tumor Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Product
        • 6.3.2.2.4. By Specimen
    • 6.3.3. Canada Circulating Tumor Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Product
        • 6.3.3.2.4. By Specimen

7. Europe Circulating Tumor Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Product
    • 7.2.4. By Specimen
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Circulating Tumor Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Product
        • 7.3.1.2.4. By Specimen
    • 7.3.2. Germany Circulating Tumor Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Product
        • 7.3.2.2.4. By Specimen
    • 7.3.3. United Kingdom Circulating Tumor Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Product
        • 7.3.3.2.4. By Specimen
    • 7.3.4. Italy Circulating Tumor Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Product
        • 7.3.4.2.4. By Specimen
    • 7.3.5. Spain Circulating Tumor Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Product
        • 7.3.5.2.4. By Specimen

8. Asia-Pacific Circulating Tumor Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Product
    • 8.2.4. By Specimen
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Circulating Tumor Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Product
        • 8.3.1.2.4. By Specimen
    • 8.3.2. India Circulating Tumor Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Product
        • 8.3.2.2.4. By Specimen
    • 8.3.3. South Korea Circulating Tumor Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Product
        • 8.3.3.2.4. By Specimen
    • 8.3.4. Japan Circulating Tumor Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Product
        • 8.3.4.2.4. By Specimen
    • 8.3.5. Australia Circulating Tumor Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Product
        • 8.3.5.2.4. By Specimen

9. South America Circulating Tumor Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Product
    • 9.2.4. By Specimen
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Circulating Tumor Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Product
        • 9.3.1.2.4. By Specimen
    • 9.3.2. Argentina Circulating Tumor Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Product
        • 9.3.2.2.4. By Specimen
    • 9.3.3. Colombia Circulating Tumor Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Product
        • 9.3.3.2.4. By Specimen

10. Middle East and Africa Circulating Tumor Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Product
    • 10.2.4. By Specimen
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Circulating Tumor Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Product
        • 10.3.1.2.4. By Specimen
    • 10.3.2. Saudi Arabia Circulating Tumor Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Product
        • 10.3.2.2.4. By Specimen
    • 10.3.3. UAE Circulating Tumor Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Product
        • 10.3.3.2.4. By Specimen

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Product & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Greiner Bio One International GmbH
    • 15.6.2. LineaRx, Inc. (Vitatex, Inc.)
    • 15.6.3. Bio-Techne Corporation
    • 15.6.4. Biolidics Limited
    • 15.6.5. Fluxion Biosciences, Inc.
    • 15.6.6. Creatv MicroTech, Inc.
    • 15.6.7. Canopus Bioscience Ltd.
    • 15.6.8. AVIVA Biosciences Corp
    • 15.6.9. Miltenyi Biotec Inc
    • 15.6.10. QIAGEN NV

16. Strategic Recommendations